| Definition and initial validation of a lupus low disease activity state (LLDAS) K Franklyn, CS Lau, SV Navarra, W Louthrenoo, A Lateef, L Hamijoyo, ... Annals of the rheumatic diseases 75 (9), 1615-1621, 2016 | 610 | 2016 |
| Global epidemiology of systemic lupus erythematosus MRW Barber, C Drenkard, T Falasinnu, A Hoi, A Mak, NY Kow, ... Nature Reviews Rheumatology 17 (9), 515-532, 2021 | 385 | 2021 |
| Clinical associations of serum interleukin-17 in systemic lupus erythematosus FB Vincent, M Northcott, A Hoi, F Mackay, EF Morand Arthritis research & therapy 15, 1-9, 2013 | 167 | 2013 |
| Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice AY Hoi, MJ Hickey, P Hall, J Yamana, KM O’Sullivan, LL Santos, ... The Journal of Immunology 177 (8), 5687-5696, 2006 | 154 | 2006 |
| Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ... Arthritis research & therapy 19, 1-11, 2017 | 138 | 2017 |
| Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases AY Hoi, MN Iskander, EF Morand Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets …, 2007 | 131 | 2007 |
| TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy SA Summers, A Hoi, OM Steinmetz, KM O’Sullivan, JD Ooi, D Odobasic, ... Journal of autoimmunity 35 (4), 291-298, 2010 | 130 | 2010 |
| Brief report: interleukin‐38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus I Rudloff, J Godsell, CA Nold‐Petry, J Harris, A Hoi, EF Morand, MF Nold Arthritis & Rheumatology 67 (12), 3219-3225, 2015 | 127 | 2015 |
| Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort KS Yap, M Northcott, ABY Hoi, EF Morand, M Nikpour Lupus science & medicine 2 (1), e000064, 2015 | 111 | 2015 |
| Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study V Golder, R Kandane-Rathnayake, M Huq, HT Nim, W Louthrenoo, ... The Lancet Rheumatology 1 (2), e95-e102, 2019 | 110 | 2019 |
| Analysis of serum interleukin (IL)-1β and IL-18 in systemic lupus erythematosus R Mende, FB Vincent, R Kandane-Rathnayake, R Koelmeyer, E Lin, ... Frontiers in immunology 9, 1250, 2018 | 108 | 2018 |
| Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus J Godsell, I Rudloff, R Kandane-Rathnayake, A Hoi, MF Nold, EF Morand, ... Scientific reports 6 (1), 34604, 2016 | 103 | 2016 |
| Independent association of glucocorticoids with damage accrual in SLE D Apostolopoulos, R Kandane-Rathnayake, S Raghunath, A Hoi, ... Lupus science & medicine 3 (1), e000157, 2016 | 94 | 2016 |
| Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal … FB Vincent, M Northcott, A Hoi, F Mackay, EF Morand Lupus 22 (9), 873-884, 2013 | 92 | 2013 |
| Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic V Golder, K Connelly, M Staples, E Morand, A Hoi Lupus 22 (13), 1425-1430, 2013 | 78 | 2013 |
| Discordance of patient and physician health status concerns in systemic lupus erythematosus V Golder, JJY Ooi, AS Antony, T Ko, S Morton, R Kandane-Rathnayake, ... Lupus 27 (3), 501-506, 2018 | 77 | 2018 |
| Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study D Apostolopoulos, R Kandane-Rathnayake, W Louthrenoo, SF Luo, ... The Lancet Rheumatology 2 (1), e24-e30, 2020 | 59 | 2020 |
| Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ... Arthritis research & therapy 18, 1-9, 2016 | 58 | 2016 |
| Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study V Golder, R Kandane-Rathnayake, M Huq, W Louthrenoo, SF Luo, ... The Lancet Rheumatology 1 (2), e103-e110, 2019 | 53 | 2019 |
| The need to define treatment goals for systemic lupus erythematosus K Franklyn, A Hoi, M Nikpour, EF Morand Nature Reviews Rheumatology 10 (9), 567-571, 2014 | 50 | 2014 |
